11:45 AM - 1:30 PM
We have all seen the press talking about "The Gap"? in Life Science funding. It is reported that many good early stage technologies go unfunded because the focus of today's investors are for more developed technologies. In Life Sciences, this usually means companies that have developed far enough along to have patient data or be close to the clinic.
However, some of the right companies are getting funded. Come to hear from one such successful company !
You will get the story from a variety of different perspectives and have the opportunity to ask questions to see how this might apply to your early stage business, whether it be life science or high technology.
The Company will share with you some of the challenges and what they had to do to keep the science moving forward while focusing their attention on getting ready to take advantage of the funding opportunity when it became available.
--The Investor - and angel investor - will share with you some of the elements that they looked for prior to investing in a risky early stage investment, the process of evaluation, and why this company rose to meet those challenges.
--The VC, who is following this company closely, watching where it is headed and what it will take to bring them to the table for the next round of funding.
--The legal counsel, who helped the company put the business and the IP in shape to be attractive to investors and what you should plan for if you want your company to get funded.
Please come, prepared to listen and ask questions and learn what it will take for your company to be successful
About Our Speaker(s)
Jack J Florio
Vice President, Communications
and BioMedTrak Investor
San Diego Tech Coast Angels
John P. Schmid
Chief Financial Officer
Rx3 Pharmaceuticals, Inc.
6310 Nancy Ridge Drive, Suite 105
San Diego Tech Coast Angels
Julie M. Robinson, Esq.
Cooley Godward LLP
Kerry Dance, Ph.D.
Bio of Kerry Dance, Managing Director - Hamilton Bioventures:
Dr. Dance has 25 years of executive experience, both as a scientist and
a leader, and has focused on life sciences since the beginning the
formation of Hamilton in 1998. Dr. Dance came to San Diego in 1978 and
became President of General Atomics Corporation. While at General
Atomics he founded an in-house venture enterprise (one of the first in
San Diego) which produced a successful track record and spun off
several successful enterprises, including the San Diego Super Computer
Dr. Kerry Dance currently is the Chairman of the Board of Directors of
Angstrom Pharmaceuticals, is a Director of PhotoThera and observes on
the Board of Ceregene. He was a founding Board member of Egea
Biosciences and was actively involved in direction of the company as
well as its sale to J&J in 2004. Dr. Dance was also heavily involved in
the sourcing of PhotoThera and Q3DM and served on the Boards of
Directors for both of these companies during the crucial early years.
Dr. Dance led the due diligence on Ceregene and was able to bring both
MPM Capital and Alta Partners into a $32 million first venture capital
financing round for Ceregene with a guaranteed position for Hamilton in
the round. He has previously served as CEO of Advanced Distillation
Technology, a seawater desalination company, as well as President of
the S-Cubed Division of Maxwell Laboratories, Inc., and Vice President
of Technology for Aerojet General Corporation.
Dr. Dance attended Stanford University where he received a Ph.D. in
Mechanical Engineering with a Nuclear Option and Math Minor and B.S.
and M.S. degrees in Engineering Science.
Bio of John Schmid, Chief Financial Office, Rx3 Pharmaceuticals, Inc.:
John co-founded Rx3 with scientists from Elitra and Syrrx in 2004. He has over 21 years experience in finance and senior management. John was previously the co-founder and Chief Financial Officer of GeneFormatics, Inc., which he co-founded with scientists from The Scripps Research Institute and merged into another San Diego biotech company. John previously held the positions of Chief Financial Officer of Endonetics, Inc. (acquired by Medtronic), Associate with Idanta Partners, a San Diego venture capital firm, Vice President at Home Fed Bank and Financial Analyst for J.P. Morgan. He is a past board member and past President of the San Diego Venture Group. Mr. Schmid received a BA in Economics from Wesleyan University and an MBA from the University of San Diego.
Bio of Julia Brown, San Diego Tech Coast Angels:
Julia R Brown is a member of the Board of Directors of Tanox, Inc., MediQuest Therapeutics, Inc. and Rx3 Pharmaceuticals, Inc. She serves on the business advisory board of CovX Pharmaceuticals. Julia is a member of the board of the University of California, San Diego Foundation, CONNECT, the La Jolla Institute for Molecular Medicine, and the Veterans Medical Research Foundation associated with the Veterans Hospital in San Diego. She is a Tech Coast Angel, a member of BIOCOM, Corporate Director’s Forum, and Athena.
From 2000-2003, Julia was Executive Vice President of Amylin Pharmaceuticals, Inc. and continues to serve as Advisor to the CEO. Prior to joining Amylin, Julia was Executive Vice President of Dura Pharmaceuticals, Inc. She was with Dura from 1995-1999. Julia spent over 25 years with Eli Lilly and Company in progressively more senior roles. From 1992-1994, Julia was Vice President of IVAC Corporation and General Manager of its Vital Signs Division (a Lilly subsidiary). She was Vice President of Worldwide Marketing for Hybritech (another Lilly subsidiary), and led global marketing from1986-1992. She held a variety of positions in the pharmaceutical division, including eight years in the Company’s international division. She did basic research in antimicrobials from 1969-1973. Julia is a graduate of Louisiana Tech University where she studied microbiology and biochemistry.
Bio of Julie M. Robinson, Partner, Cooley Godward LLP:
Julie M. Robinson is a partner in the Cooley Godward Business department. She joined the Firm in 1993 and is resident in the San Diego office.
Ms. Robinson specializes in corporate and securities law, with an emphasis on the representation of emerging and public technology companies. Ms. Robinson advises clients on a broad range of general corporate and securities laws matters, including general corporate governance issues, disclosure issues and reporting requirements, equity incentives, employee compensation and benefits and the formation of new businesses. Ms. Robinson has extensive experience representing clients in public and private equity and debt financings, including initial public offerings and follow-on public offerings, public and private company mergers and acquisitions, venture financings and joint ventures.
Prior to joining the Firm, Ms. Robinson was a corporate associate in the Los Angeles office of O’Melveny & Myers.
Ms. Robinson graduated valedictorian of Pepperdine University School of Law in 1991. In 1989, Ms. Robinson served as a summer extern to the Hon. Dorothy Nelson, U.S. Circuit Court of Appeals, Ninth Circuit. Ms. Robinson received a B.A. in Political Science from the University of Rochester in 1978.
Prior to attending law school Ms. Robinson was employed for several years as a consultant and analyst for an international insurance brokerage. Subsequent to that, Ms. Robinson was in the yacht chartering business in Marina del Rey, California, where she both started her own company chartering luxury yachts for business and pleasure and managed an established yacht chartering company.
Ms. Robinson is a member of the State Bar of California, the American Bar Association and the San Diego County Bar Association. Ms. Robinson is a co-author of “Venture Capital and Public Offering Negotiation” Aspen Law and Business,Inc., 2002, Chapters 6 through 14.
Event Date and Venue
This event will be held from 11:45 AM - 1:30 PM on Wednesday, October 25, 2006 at:
Cooley Godward Kronish LLP
4401 Eastgate Mall
San Diego, California 92121
11:45 AM - 12:15 PM Registration/Lunch/Networking
12:15 PM - 1:30 PM Program/Q&A
Pre-registration for this event is closed and on-site registrations will not be accepted.
About Our Sponsor(s)
Cooley Godward Kronish is a national law firm for the converging worlds of high technology, high finance and high-stakes litigation. We are counselors, strategists and advocates for the foremost private and public companies across a wide variety of industries and in all major technology fields. Our clients include business organizations, entrepreneurs, venture capitalists, financial institutions, private equity firms, professional services firms and real estate owners and developers. Cooley has approximately 550 attorneys and represents clients in more than 20 industries.
In helping our clients grow their businesses, we draw upon our experience with industry-leading public companies and financial institutions, as well as our extensive work with innovative entrepreneurs and emerging growth companies. Whether forming creative start-ups, facilitating seed and mezzanine financing, handling initial public offerings and mergers and acquisitions, or providing strategic prelitigation counseling and representation in adversarial proceedings, Cooley is as equally adept at representing two-person start-ups as it is Fortune 500 companies.
Attorneys in Cooley’s preeminent Business practice are well known for their expertise in the areas of venture capital and private equity, corporate securities, mergers and acquisitions, life sciences and technology transactions, tax and real estate, making Cooley a go-to firm for clients seeking counseling in these areas.
We also have a national reputation for protecting our clients' business interests and assets through timely prelitigation counseling and hard-fought adversarial proceedings before federal and state courts nationwide, regulatory agencies and alternative dispute resolution forums. Our 250-attorney Litigation practice includes prominent trial lawyers and more than nine former federal prosecutors with deep experience handling high-profile complex commercial, white collar crime, securities fraud and intellectual property cases, as well as complex restructurings and major bankruptcies.
Using a team approach, we draw upon our broad base of expertise to provide our clients with high-quality, cost-effective legal advice tailored to their particular needs. Our breadth of expertise, together with our entrepreneurial spirit and commitment to excellence, enables us to address our clients’ most challenging legal matters.
About Our Partner(s)
For more info regarding registration or event details, please contact WITI San Diego (858-344-3825) ([email protected]).
For more details about pre-registration, contact Tech Support.